-
Mashup Score: 2Wearable technology for heart rhythm monitoring in children. - 2 day(s) ago
Wearable technology has become increasingly prevalent. A number of devices are available on the market, ranging from smartphones to eyeglasses, headbands, and necklaces to monitor and record a multitude of vital signs and markers of health. As technology rapidly advances, devices will ideally become more convenient and affordable, and their presence will become ubiquitous in the homes of all of our patients.
Source: www.heartrhythmjournal.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 3Reply to the editor -- Postural Orthostatic Tachycardia Syndrome After COVID-19 Vaccination - 3 day(s) ago
We thank Drs. Daungsupawong and Wiwanit for their constructive comments. To avoid bias, the POTS clinic did not elicit vaccination status unless volunteered. All symptoms included in our report were prospectively collected and documented. We agree that longitudinal research with a control group would be required to document a causal association between vaccination and POTS.
Source: www.heartrhythmjournal.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 6Risk of incident atrial fibrillation after COVID-19 infection: A systematic review and meta-analysis - 4 day(s) ago
Data regarding the risk of atrial fibrillation (AF) during the post-acute phase of COVID-19 are lacking.
Source: www.heartrhythmjournal.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 32
Atrial arrhythmogenic substrate is a key determinant of atrial fibrillation (AF) recurrence after pulmonary vein isolation (PVI), and reduced conduction-velocities have been linked to adverse outcome. However, a non-invasive method to assess such electrophysiological substrate is not available to date.
Source: www.heartrhythmjournal.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 28Durability of Thermal Pulmonary Vein Isolation in Persistent Atrial Fibrillation Assessed by Mandated Repeat Invasive Study - 4 day(s) ago
No study has assessed durability of pulmonary vein isolation (PVI) with radiofrequency (RF) and Cryoballoon (CB) in patients with persistent AF. These data are especially lacking for those with significantly diseased left atria (LA).
Source: www.heartrhythmjournal.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 147
The benefit of catheter ablation in patients with atrial fibrillation (AF) for patients with heart failure with preserved ejection fraction (HFpEF) remains uncertain.
Source: www.heartrhythmjournal.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 10Efficacy and safety of once-daily carvedilol in patients with atrial fibrillation: A randomized, double-blind, placebo-controlled trial - 4 day(s) ago
Heart rate (HR) control is a mainstay of atrial fibrillation (AF) management. Guidelines recommend first-line β-blockers for HR control in paroxysmal, persistent, or permanent AF.1 Carvedilol, a nonselective β-blocker, has a documented HR-lowering effect; in a dose-escalation study of Japanese patients with chronic AF (AF Carvedilol study), each dose of carvedilol (5, 10, or 20 mg once daily) significantly reduced HR from baseline (HR ≥80 beats/min) during 6 weeks of treatment.2 Although off-label carvedilol indications include AF,3 there are currently no phase 3 clinical trial data to support carvedilol use for HR control in patients with AF.
Source: www.heartrhythmjournal.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 10Atrial Fibrillation Ablation in Patients with Pulmonary Hypertension: Multicenter Experience - 5 day(s) ago
Pulmonary hypertension (PH) is a progressive condition characterized by pulmonary vascular remodeling and elevated pulmonary arterial pressure. Atrial arrhythmias are common in PH and may contribute to right ventricular failure and death1,2. We retrospectively identified patients with pre-capillary PH who underwent catheter ablation for AF at four high-volume ablation centers. Included patients had an established clinical diagnosis of PH, with suspected pre-capillary etiology, and at least one right heart catheterization showing mean pulmonary artery pressure >20 mm Hg and pulmonary capillary wedge pressure ≤15 mm Hg.
Source: www.heartrhythmjournal.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 14Incidence of Newly Recognized Atrial Fibrillation in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Mavacamten - 5 day(s) ago
Mavacamten is a cardiac myosin inhibitor that has been shown to reduce left ventricular outflow tract obstruction in obstructive hypertrophic cardiomyopathy (oHCM).1 In late-stage clinical trials, atrial fibrillation (AF) represented an adverse event in 2-4 % of the patients randomized to mavacamten.1,2 However, the effect of mavacamten on the frequency and management of new/recurrent AF episodes in oHCM receiving mavacamten following its Food and Drug Administration (FDA) approval remains only partially explored.
Source: www.heartrhythmjournal.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 34
Idiopathic atypical (non-cavotricupid isthmus [CTI]-dependent) atrial flutter (IAAFL) may be seen in patients without structural heart disease and without previous cardiac surgery or ablation.
Source: www.heartrhythmjournal.comCategories: General Medicine News, Cardiology News and JournTweet
Wearable technology for heart rhythm monitoring in children https://t.co/Lva7AINGlW